Stock Track | 10x Genomics Plunges 5% in Post-Market as Q2 Revenue Declines and Swings to Loss

Stock Track08-07 13:50

Shares of 10x Genomics, Inc. (TXG) experienced a sharp 5.00% decline in post-market trading, reflecting a negative investor reaction to the company's second-quarter financial results. While headline results exceeded analyst estimates, a deeper look revealed a significant year-over-year contraction in revenue and a shift from profitability to a net loss, triggering selling pressure.

The company reported Q2 revenue of $151.0 million, down 12.6% from $172.9 million a year ago, and a net loss of $17.9 million, swinging from earnings of $0.28 per share in the prior-year period. Although the reported loss of $0.14 per share beat consensus estimates of a $0.24 loss, and revenue exceeded the $146.8 million forecast, the fundamental deterioration in top-line growth and the profit-to-loss reversal weighed heavily on sentiment. Operating expenses also climbed 39% to $132.1 million, further compressing margins.

10x Genomics raised its full-year 2026 revenue guidance to a range of $610 million to $630 million, up from $600 million to $625 million, citing strong early order flow for its Atera product. However, this raised outlook was insufficient to offset immediate concerns over the quarterly contraction, leading to the post-market sell-off.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136005146?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 13:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136005146","market":"hk","top_or_hot":-1,"title":"Stock Track | 10x Genomics Plunges 5% in Post-Market as Q2 Revenue Declines and Swings to Loss","media":"Stock Track","content":"<p>Shares of 10x Genomics, Inc. (TXG) experienced a sharp 5.00% decline in post-market trading, reflecting a negative investor reaction to the company's second-quarter financial results. While headline results exceeded analyst estimates, a deeper look revealed a significant year-over-year contraction in revenue and a shift from profitability to a net loss, triggering selling pressure.</p>\n<p>The company reported Q2 revenue of $151.0 million, down 12.6% from $172.9 million a year ago, and a net loss of $17.9 million, swinging from earnings of $0.28 per share in the prior-year period. Although the reported loss of $0.14 per share beat consensus estimates of a $0.24 loss, and revenue exceeded the $146.8 million forecast, the fundamental deterioration in top-line growth and the profit-to-loss reversal weighed heavily on sentiment. Operating expenses also climbed 39% to $132.1 million, further compressing margins.</p>\n<p>10x Genomics raised its full-year 2026 revenue guidance to a range of $610 million to $630 million, up from $600 million to $625 million, citing strong early order flow for its Atera product. However, this raised outlook was insufficient to offset immediate concerns over the quarterly contraction, leading to the post-market sell-off.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 10x Genomics Plunges 5% in Post-Market as Q2 Revenue Declines and Swings to Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 10x Genomics Plunges 5% in Post-Market as Q2 Revenue Declines and Swings to Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-07 13:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of 10x Genomics, Inc. (TXG) experienced a sharp 5.00% decline in post-market trading, reflecting a negative investor reaction to the company's second-quarter financial results. While headline results exceeded analyst estimates, a deeper look revealed a significant year-over-year contraction in revenue and a shift from profitability to a net loss, triggering selling pressure.</p>\n<p>The company reported Q2 revenue of $151.0 million, down 12.6% from $172.9 million a year ago, and a net loss of $17.9 million, swinging from earnings of $0.28 per share in the prior-year period. Although the reported loss of $0.14 per share beat consensus estimates of a $0.24 loss, and revenue exceeded the $146.8 million forecast, the fundamental deterioration in top-line growth and the profit-to-loss reversal weighed heavily on sentiment. Operating expenses also climbed 39% to $132.1 million, further compressing margins.</p>\n<p>10x Genomics raised its full-year 2026 revenue guidance to a range of $610 million to $630 million, up from $600 million to $625 million, citing strong early order flow for its Atera product. However, this raised outlook was insufficient to offset immediate concerns over the quarterly contraction, leading to the post-market sell-off.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXG","symbol_name":"10x Genomics, Inc.","start_time":0,"source_url":"","article_id":"1136005146","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136005146","pubTimestamp":1786081818,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of 10x Genomics, Inc. (TXG) experienced a sharp 5.00% decline in post-market trading, reflecting a negative investor reaction to the company's second-quarter financial results. While headline...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TXG":"10x Genomics, Inc."},"translate_title":"股票跟踪 | 10x Genomics 第二季度收入下降并转为亏损，盘后暴跌 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXG":1},"content_text":"Shares of 10x Genomics, Inc. (TXG) experienced a sharp 5.00% decline in post-market trading, reflecting a negative investor reaction to the company's second-quarter financial results. While headline results exceeded analyst estimates, a deeper look revealed a significant year-over-year contraction in revenue and a shift from profitability to a net loss, triggering selling pressure.\nThe company reported Q2 revenue of $151.0 million, down 12.6% from $172.9 million a year ago, and a net loss of $17.9 million, swinging from earnings of $0.28 per share in the prior-year period. Although the reported loss of $0.14 per share beat consensus estimates of a $0.24 loss, and revenue exceeded the $146.8 million forecast, the fundamental deterioration in top-line growth and the profit-to-loss reversal weighed heavily on sentiment. Operating expenses also climbed 39% to $132.1 million, further compressing margins.\n10x Genomics raised its full-year 2026 revenue guidance to a range of $610 million to $630 million, up from $600 million to $625 million, citing strong early order flow for its Atera product. However, this raised outlook was insufficient to offset immediate concerns over the quarterly contraction, leading to the post-market sell-off.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136005146","isCrawlerRequest":true}